Company news

Halozyme Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Halozyme Reports Third Quarter 2021 Results

November 1, 2021

Halozyme To Host Third Quarter 2021 Financial Results Webcast and Conference Call

October 18, 2021

Halozyme to Participate in the 2021 Cantor Virtual Global Healthcare Conference

September 14, 2021

Halozyme to Present at Wells Fargo 2021 Virtual Healthcare Conference

August 25, 2021

Halozyme Reports Second Quarter 2021 Results

August 8, 2021

Halozyme to Participate in Canaccord Genuity 41st Annual Growth Conference

July 29, 2021

Halozyme To Host Second Quarter 2021 Financial Results Webcast and Conference Call

July 26, 2021

ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIV

June 21, 2021

ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV

June 21, 2021

Halozyme Announces Janssen Receives European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation for Newly Diagnosed Systemic Light-chain Amyloidosis and Pre-Treated Multiple Myeloma

June 21, 2021

Halozyme Highlights Data Presentations by Collaborators for Therapies Utilizing ENHANZE® at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

May 31, 2021

Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE®

May 20, 2021

Halozyme Reports First Quarter 2021 Results

May 9, 2021

Halozyme to Present at BofA Securities 2021 Virtual Health Care Conference

April 28, 2021

Halozyme To Host First Quarter 2021 Financial Results Webcast And Conference Call

April 19, 2021

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027

February 23, 2021

Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027

February 22, 2021

Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results

February 22, 2021

Halozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference Call

February 9, 2021

Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO® (Daratumumab And Hyaluronidase-fihj) As Treatment For Newly Diagnosed Patients With Light Chain (AL) Amyloidosis

January 14, 2021

Halozyme Provides 2021 Financial Guidance Highlighted By Strong Revenue And EPS Growth

January 10, 2021

Halozyme To Present Virtually At The 39th Annual J.P. Morgan Healthcare Conference

January 3, 2021

Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology

November 22, 2020

Halozyme Raises Full Year 2020 Guidance

November 22, 2020

Halozyme To Participate In Fireside Chat For The Piper Sandler 32nd Annual Virtual Healthcare Conference

November 17, 2020

Halozyme Announces CHMP Recommends EU Approval Of Roche's Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For HER2-Positive Breast Cancer

November 12, 2020

Halozyme Announces Upcoming Data Presentations at American Society of Hematology Annual Meeting For APOLLO and ANDROMEDA Phase 3 Studies By Janssen Evaluating Subcutaneous Daratumumab Utilizing ENHANZE®

November 4, 2020

Halozyme Reports Third Quarter 2020 Results And Raises Full Year 2020 Guidance

November 1, 2020

Halozyme To Host THIRD Quarter 2020 Financial Results webcast and Conference Call

October 21, 2020

Halozyme Announces Expansion Of Collaboration And License Agreement With argenx For ENHANZE® Technology

October 5, 2020

Halozyme Announces Poster Presentation Of Data From Roche's Phase 1b Study Evaluating Atezolizumab For Subcutaneous Administration Utilizing Enhanze® In Non-Small Cell Lung Cancer

September 16, 2020

Halozyme Announces Janssen Submission For FDA Approval Of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) For The Treatment Of Patients With Light Chain (AL) Amyloidosis

September 9, 2020

Halozyme To Present At Upcoming Virtual Investor Conferences

September 8, 2020

Halozyme To Participate In 2020 Wells Fargo Virtual Healthcare Conference

September 1, 2020

Halozyme Reports Significant Recent Achievements And Second Quarter 2020 Results

August 9, 2020

Halozyme To Present At Canaccord Genuity 40th Annual Growth Conference

August 3, 2020

Halozyme To Host Second Quarter 2020 Financial Results Webcast And Conference Call

July 28, 2020

Halozyme Announces Roche Receives FDA Approval For Phesgo™ (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Breast Cancer

June 28, 2020

Halozyme To Receive $10 Million Milestone Payment From Janssen

June 21, 2020

Halozyme To Participate In The BMO 2020 Prescriptions For Success Healthcare Conference

June 16, 2020

Halozyme Announces Findings From Janssen's Phase 3 Andromeda Study Evaluating Subcutaneous Daratumumab Utilizing ENHANZE® In Light-Chain Amyloidosis Presented At European Hematology Association 25th Annual Congress

June 12, 2020

Halozyme Announces Janssen Receives European Marketing Authorization For Subcutaneous DARZALEX® Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma

June 3, 2020

Halozyme To Receive $15 Million Milestone Payment From Janssen

May 13, 2020

Halozyme Reports First Quarter 2020 Results

May 10, 2020

Halozyme To Present At The Bank Of America Securities 2020 Healthcare Conference

May 6, 2020

Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO™ Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma

April 30, 2020

Halozyme Announces Janssen's Receipt Of CHMP Positive Opinion For DARZALEX® Subcutaneous Formulation Utilizing Halozyme's ENHANZE® Technology For Patients With Multiple Myeloma

April 29, 2020

Halozyme To Host First Quarter 2020 Financial Results Webcast and Conference Call

April 27, 2020

Halozyme Announces Janssen Submits New Drug Application In Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme's ENHANZE® Technology For Patients With Multiple Myeloma

April 25, 2020

Halozyme Announces Change Of Location Of Annual Stockholders' Meeting

April 2, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 65 decks. Every deck is listed under its year.